[Expert Consensus on the Diagnosis and Treatment of Respiratory Diseases Exacerbated by Nonsteroidal Anti-Inflammatory Drugs (2024, Chengdu)].
Juan Meng,Jing Ye,LiJiang Zhang,YuanTeng Xu,WenLong Liu,YuCheng Yang,XiangDong Wang,Yan Jiang,QianHui Qiu,Jian Li,ShaoQing Yu,Feng Liu,HongFei Lou,HongTian Wang,GuoDong Yu,Rui Xu,CuiDa Meng,Na Sun,JianJun Chen,Ming Zeng,ZhiHai Xie,YueJi Sun,Juan Tang,KeQing Zhao,WeiTian Zhang,ZhaoHui Shi,ChengLi Xu,YanLi Yang,MeiPing Lu,HuiPing Ye,Xin Wei,Bin Sun,YunFang An,YaNan Sun,YuRong Gu,TianHong Zhang,Luo Ba,QinTai Yang,Yu Xu,Gui Yang,HaiYu Hong,KeJun Zuo,HuaBin Li
DOI: https://doi.org/10.13201/j.issn.2096-7993.2024.06.001
2024-01-01
Abstract:Non-steroidal anti-inflammatory drugs-exacerbated respiratory disease (N-ERD) is a chronic respiratory disease characterized by eosinophilic inflammation, featuring chronic rhinosinusitis (CRS), asthma, and intolerance to cyclooxygenase 1 (COX-1) inhibitors. The use of these medications can lead to an acute worsening of rhinitis and asthma symptoms. This condition has not yet received sufficient attention in China, with a high rate of misdiagnosis and a lack of related research. The Chinese Rhinology Research Group convened a group of leading young experts in otolaryngology from across the country, based on the latest domestic and international evidence-based medical practices to formulate this consensus.The consensus covers the epidemiology, pathogenesis, clinical manifestations, diagnostic methods, and treatment strategies for N-ERD, including pharmacotherapy, surgery, biologic treatments, and desensitization therapy. The goal is to improve recognition of N-ERD, reduce misdiagnosis, and enhance treatment outcomes.